BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Idera Pharmaceuticals, Inc. 

167 Sidney Street

Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-679-5500 Fax: 617-679-5592


SEARCH JOBS

View Clinical Trials from BioPharm Insight

Idera Pharmaceuticals develops drug candidates to treat infectious diseases, autoimmune diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants. Our proprietary drug candidates are designed to modulate specific Toll-like Receptors, which are a family of immune system receptors that direct immune system responses. Our pioneering DNA and RNA chemistry expertise enables us to create drug candidates for internal development and generates opportunities for multiple collaborative alliances.

For more information, visit www.iderapharma.com.

 Key Statistics


Email: info@iderapharma.com
Ownership:

Web Site: Idera Pharmaceuticals, Inc.
Employees:
Symbol: IDRA
 









 Company News
Idera Pharmaceuticals, Inc. (IDRA) Reports Second Quarter 2014 Financial Results And Provides Corporate Update 8/12/2014 8:44:39 AM
Idera Pharmaceuticals, Inc. (IDRA) And The Myositis Association Join Forces To Advance The Clinical Development Of A Novel TLR Antagonist, IMO-8400, For The Treatment Of Myositis 8/7/2014 10:37:11 AM
Idera Pharmaceuticals, Inc. (IDRA) And Collaborators Publish Promising Preclinical Data Targeting Microrna With Gene Silencing Oligonucleotide Technology 8/6/2014 10:46:15 AM
Idera Pharmaceuticals, Inc. (IDRA) To Host Conference Call And Webcast To Report Second Quarter 2014 Financial Results 8/5/2014 10:00:37 AM
Idera Pharmaceuticals, Inc. (IDRA) To Be Added To The Russell 3000® And Russell 2000#0174; Indexes 6/27/2014 9:34:49 AM
Idera Pharmaceuticals, Inc. (IDRA) To Participate In A Panel Discussion At The Piper Jaffray Genomerx Symposium 6/17/2014 1:23:06 PM
Idera Pharmaceuticals, Inc. (IDRA) To Present At The Nucleic Acid Summit 2014 6/16/2014 8:58:38 AM
Idera Pharmaceuticals, Inc. (IDRA) To Present At The Jefferies and Co. 2014 Global Healthcare Conference 5/28/2014 7:40:17 AM
Idera Pharmaceuticals, Inc. (IDRA) Reports First Quarter 2014 Financial Results And Provides Update On Key Programs And Business Strategy 5/13/2014 7:28:21 AM
Idera Pharmaceuticals, Inc. (IDRA) Announces Agreement With Abbott Laboratories (ABT) To Develop A Companion Diagnostic For IMO-8400 In Genetically Defined Forms Of B-Cell Lymphoma 5/8/2014 11:57:28 AM
12345678910...